Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Short Interest Update

Hansa Biopharma AB (publ) (OTCMKTS:HNSBFGet Rating) saw a significant growth in short interest in August. As of August 31st, there was short interest totalling 369,400 shares, a growth of 12.0% from the August 15th total of 329,800 shares. Based on an average daily volume of 1,300 shares, the days-to-cover ratio is currently 284.2 days.

Hansa Biopharma AB (publ) Price Performance

Shares of HNSBF opened at $5.75 on Wednesday. Hansa Biopharma AB has a one year low of $5.75 and a one year high of $5.75. The business’s 50 day simple moving average is $5.68 and its 200-day simple moving average is $6.42.

Analyst Upgrades and Downgrades

Separately, HC Wainwright lifted their price objective on Hansa Biopharma AB (publ) from SEK 223 to SEK 244 and gave the company a “buy” rating in a report on Wednesday, July 20th.

About Hansa Biopharma AB (publ)

(Get Rating)

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome.

See Also

Receive News & Ratings for Hansa Biopharma AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hansa Biopharma AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.